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Abstract
Introduction: Small bowel adenocarcinoma is a rare malignancy associated with a poor prognosis and there is
little evidence of effective treatment. Recurrent small bowel adenocarcinoma is an intractable disease for which
there is little information available regarding its treatment by palliative therapy. We present a case of recurrent
small bowel adenocarcinoma successfully treated by cytoreductive surgery and palliative chemotherapy.
Case presentation: We report the case of a 72-year-old Japanese female who developed a peritoneal metastasis
from recurrent small bowel adenocarcinoma after curative resection and adjuvant chemotherapy with S-1 and
polysaccharide K. She underwent cytoreductive surgery followed by chemotherapy with folinic acid/fluorouracil/
oxaliplatin and folinic acid/fluorouracil/irinotecan with polysaccharide K. Subsequently, no sign of a recurrence was
observed 42 months after the second operation.
Conclusion: To the best of our knowledge, this is the first case report of the successful treatment of peritoneal
metastasis from small bowel adenocarcinoma by cytoreductive surgery and combination chemotherapy (folinic
acid/fluorouracil/oxaliplatin and folinic acid/fluorouracil/irinotecan with polysaccharide K).
Introduction
Primary malignancies of the small bowel represent only
2.4% of all gastrointestinal malignancies [1]. Adenocarci-
noma is the most common malignancy of the small
bowel, comprising about one-third of all small bowel
malignancies [2]. The most frequent location for small
bowel adenocarcinoma (SBA) is the duodenum (52%-
55%), followed by the jejunum (18%-25%) and the ileum
(13%), and not otherwise specified (10%-14%) [2,3].
Non-specific symptoms and the lack of useful diagnostic
methods results in a delayed diagnosis of SBA. The ratio
of SBA diagnosed at stage I, stage II, stage III and stage
IV has been reported to be 4%-12%, 20%-27%, 26%-39%
and 32%-35%, respectively [2,3]. The five-year survival
rate is 26%-30%, with a median survival of 20 months
[2,3]. Although curative resection is the most important
prognostic factor, 67% of patients with SBA receive
curative resection [2,3]. Even after curative resection,
39% develop recurrence [3]. The usefulness of adjuvant
chemotherapy after curative resection or palliative che-
motherapy for advanced or recurrent SBA remains
unconfirmed because of the absence of a randomized
control trial (RCT) for SBA [4,5]. Only a few controlled
clinical studies for SBA treatment have been reported
[6,7] but the effectiveness of chemotherapy for advanced
SBA has been shown by retrospective studies [8].
Aggressive surgical intervention seems to be effective for
some cases of advanced or recurrent SBA [9,10]. We
report on a patient who had peritoneal metastasis from
recurrent SBA after curative surgery and adjuvant
chemotherapy. Cytoreductive surgery and palliative
chemotherapy were employed for this patient.
Case presentation
A 70-year-old Japanese female was referred to our hos-
pital for the evaluation of a small bowel obstruction.
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months before she consulted her family doctor. An
upper gastrointestinal barium study and stoppage of
ileus tube movement demonstrated a tumor in the jeju-
num near the ligament of Treitz. Abdominal computed
tomography (CT) revealed a huge uterine myoma. Dur-
ing surgery, we found the jejunal tumor located 20 cm
away from the ligament of Treitz. We performed an
enterectomy, including the regional mesentery and a
hysterectomy.
The jejunal tumor was a moderately differentiated
adenocarcinoma, penetrating the small bowel wall. None
of the 10 resected lymph nodes were positive for metas-
tasis. The tumor was diagnosed as stage II according to
the American Joint Committee on Cancer staging sys-
tem. Although the usefulness of adjuvant chemotherapy
for SBA has not been confirmed due to the lack of
RCTs, recurrence after curative resection of SBA is very
high [3,4,8]. We therefore decided to administer S-1
(Taiho Pharmaceutical, Tokyo, Japan; 80 mg/day, 2-
week administration with 2-week interval) and polysac-
charide K (PSK) for 12 months as adjuvant treatment.
S-1 has been confirmed to be an effective reagent for
gastric cancer after curative surgical resection [11]. PSK
has been confirmed as an effective adjuvant for gastric
cancer as well as colorectal cancer (CRC) after curative
resection [12,13].
Nine months after the surgery, the serum tumor mar-
ker carcinoembryonic antigen (CEA) was elevated to 6.1
ng/mL (normal, <5.0 ng/mL). Although body CT and
contrast magnetic resonance imaging (MRI) displayed
no sign of recurrence, the CEA level was elevated to 8.9
ng/mL the following month. A careful evaluation of her
medical history disclosed a hematuria. We consulted a
urologist and a bladder tumor was discovered using a
cystoscope. Positron emission tomography (PET)
revealed fludeoxyglucose accumulation in the ascending
colon, sigmoid colon, rectum and bladder. The histology
of the bladder tumor resected transurethrally revealed a
moderately differentiated adenocarcinoma invading from
outside the bladder. A colonoscopy showed tumors in
the sigmoid colon and rectum but not in the ascending
colon. A histological analysis revealed that these tumors
were well-differentiated adenocarcinomas, indicating
peritoneal dissemination of SBA. We performed a lapar-
otomy to confirm peritoneal dissemination and to
reduce the number of disseminated tumors as cytore-
ductive surgery has been shown to be useful in some
cases of peritoneal carcinomatosis from SBA [9,10].
During surgery, we found two sigmoid colon tumors,
one rectal tumor and one bladder tumor, identical to
the preoperative diagnosis (Figure 1). Besides these
tumors, nodules in the larger omentum and intestinal
mesentery were recognized. The nodule in the larger
omentum was confirmed to be an adenocarcinoma by
intraoperative rapid pathological diagnosis. We resected
these tumors, including a total cystectomy, rectosigmoi-
dectomy and omentectomy. An immunohistochemical
examination of cytokeratin (CK) 7 and CK20 exhibited
CK7 (+)/CK20 (-) tumors in the primary and metastatic
lesions. This result differed from the profile of CK7/
CK20 in CRC and was compatible with the profile of
CK7/CK20 in SBA reported previously [14]. Peritoneal
carcinomatosis of the colon and bladder was confirmed
by histological analyses (Figures 1 and 2).
The effectiveness of palliative chemotherapy for
advanced SBA has been described in a number of retro-
spective studies [8,15-17]. We therefore used folinic
acid/fluorouracil/oxaliplatin (FOLFOX) and folinic acid/
fluorouracil/irinotecan (FOLFIRI) as these regimens are
useful for patients with advanced or recurrent CRC.
After the second operation, the patient received 12
cycles of FOLFOX with PSK until the peripheral neuro-
pathy became severe. After this regimen, five cycles of
FOLFIRI with PSK were continued until no sign of
recurrence was confirmed by PET, CT and laboratory
Figure 1 Resected colon specimen. Resected colon specimen revealed three tumors in the sigmoid colon and one tumor in the rectum. The
features indicated that these were submucosal tumors.
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bined PSK with FOLFOX/FOLFIRI because we expected
PSK to enhance the efficacy of these chemotherapies.
The patient survived with no sign of recurrence 42
months after the second operation.
Discussion
SBA is rarer than CRC or gastric cancer [1]. This rarity
is associated with a poor prognosis, lack of standard
treatment and an absence of RCTs [5,18]. In the largest
retrospective study, chemotherapy with 5-FU and a pla-
tinum compound was more effective than other che-
motherapy combinations [15]. A recent prospective
study showed the usefulness of capecitabine and oxali-
platin for advanced SBA [7]. SBA treatment is usually
extrapolated from CRC or gastric cancer treatment. We
extrapolated the first treatment from that of gastric can-
cer and the second treatment from that of CRC.
Although the first treatment involving S-1 and PSK was
ineffective, the second treatment using cytoreductive
surgery and chemotherapy with FOLFOX/FOLFIRI plus
PSK was very effective. Irinotecan has been used for
advanced SBA and has shown effectiveness in those
cases [8,16,17].
Cytoreductive surgery including parietal peritonect-
omy with intraperitoneal hyperthermic chemotherapy
has demonstrated the effectiveness of peritoneal disse-
mination for abdominal malignancies including
advanced SBA [9,10,18]. Levine et al. showed that the
primary tumor site, performance status, resection status
and development of complications predicted outcomes
[19]. Although the extent of our cytoreductive surgery
was less than that of the complete cytoreductive surgery
by Marchettini et al. and Jacks et al., we resected all
visible tumors. This patient survived for an extended
period with good performance status (0), good resection
status and no complications. The pattern of peritoneal
carcinomatosis from SBA resembles that from CRC
than from gastric cancer. An extrapolation of CRC
treatment to SBA treatment seems necessary before
confirming a standard treatment.
Conclusions
Cytoreductive surgery and chemotherapy with FOLFOX/
FOLFIRI plus PSK seemed useful for recurrent small
bowel adenocarcinoma.
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